Halozyme TherapeuticsvsJohnson & Johnson

HALO and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

HALO

Halozyme Therapeutics, Inc.

$91.35

Value $10.8B

-1.82%
HALO's page

Halozyme Therapeutics (HALO) has a market value of $10.8B and Johnson & Johnson (JNJ) $652B. Over the last year, with dividends, HALO moved +30.0% and JNJ +36.6%. The P/E is 22.2 for HALO and 40.5 for JNJ. Dividend yield: HALO none, JNJ 1.95%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    HALO$10.8B

    JNJ$652B

    JNJ is 60 times HALO

  • Revenue, 12 months

    HALO$1.8B

    JNJ$99.3B

    JNJ is 55 times HALO

  • Net income, 12 months

    HALO$485M

    JNJ$16.1B

    JNJ is 33 times HALO

  • Operating margin

    HALO37.4%

    JNJ–

  • ROIC

    HALO20.7%

    JNJ12.4%

    8.3 points apart

  • P/E

    HALO22.2

    JNJ40.5

    JNJ is 1.8 times HALO

  • Dividend yield

    HALO0.0%

    JNJ2.0%

    2.0 points apart

  • 5-year return

    HALO+157.1%

    JNJ+90.9%

    66.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

HALO+157.1%

JNJ+90.9%

10020030020222023202420252026
Returns by period
PeriodHALOWith dividendsJNJWith dividends
1 year since November 19, 2025+30.0%Price +30.0%+36.6%Price +33.6%
3 years since November 20, 2023+128.3%+31.7% a yearPrice +128.3%+94.9%+24.9% a yearPrice +80.4%
5 years since November 19, 2021+157.1%+20.8% a yearPrice +157.1%+90.9%+13.8% a yearPrice +66.0%
10 years since November 21, 2016+622.7%+21.9% a yearPrice +622.7%+206.5%+11.9% a yearPrice +135.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

HALOHalozyme TherapeuticsJNJJohnson & Johnson

Valuation

HALOJNJ
Valuation
Price$91.35$270.47
Market value$10.8B$652B
Enterprise value (EV)$13.0B$679B
P/E22.240.5
P/E, 5-year median17.621.9
P/B–8.0
EV/EBIT19.238.3
Free cash flow yield8.2%3.2%

Results and growth

HALOJNJ
Results and growth
Revenue, 12 months$1.8B$99.3B
Net income, 12 months$485M$16.1B
Free cash flow, 12 months$886M$20.6B
Earnings per share, 12 months$4.01$6.59
Revenue growth, year on year37.6%6.1%
Revenue growth a year, past+39.2%over 5 years+2.7%over 5 years
EPS growth a year, past+23.0%over 5 years+14.9%over 5 years

Margins and returns on capital

HALOJNJ
Margins and returns on capital
Gross margin82.3%67.6%
Operating margin37.4%–
Net margin26.9%16.2%
ROIC20.7%12.4%
ROE282.0%19.7%

Balance sheet

HALOJNJ
Balance sheet
Cash$1.1B$17.2B
Total debt$3.3B$44.7B
Net debt / EBITDA3.21.1
Interest cover30.6×18.0×

Dividends and buybacks

HALOJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield3.2%0.9%
Shareholder yield3.2%2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: HALO or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Halozyme Therapeutics or Johnson & Johnson?

By market value, Johnson & Johnson ($652B) is about 60.5 times Halozyme Therapeutics ($10.8B), at today's prices.

How did HALO and JNJ stock do over the last 10 years?

Since November 21, 2016, HALO's price moved +622.7% and JNJ's +135.2%. With dividends: HALO +622.7% (+21.9% a year), JNJ +206.5% (+11.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, HALO or JNJ?

The dividend yield at today's price is none for Halozyme Therapeutics and 1.95% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

What is the P/E of HALO and JNJ?

At today's price, the P/E is 22.2 for HALO and 40.5 for JNJ. The median of the last five years was 17.6 and 21.9, which shows where each stands against its own past.

Which has the higher profit margins, Halozyme Therapeutics or Johnson & Johnson?

Over the last twelve months, the net margin was 26.9% for Halozyme Therapeutics and 16.2% for Johnson & Johnson, and the operating margin 37.4% and –. Revenue was $1.8B and $99.3B.

Which is the better investment, Halozyme Therapeutics or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.